食事後の低血糖症とGLUT2/GCK/GLP-1RRの特徴的な発現を有するインスリノーマ
Shinichiro Toyoda1,2, Sho Yoneda1,3, Kosuke Mukai1
1Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.
The Journal of endocrinology
|February 16, 2026
まとめ
食事後の低血糖症のみのインスリン腫患者では,グルコーストランスポーター2,グルコキナーゼ,GLP-1受容体の発現が高かった. これらのマーカーの発現の低下は,頻繁に断食する低血糖症と関連していました.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 腫瘍学 腫瘍学
- メタボリズムは
背景:
- 低血糖症は,インスリン腫患者の主な症状です.
- 以前の研究は,低血糖症のタイプに基づくインスリン腫細胞の免疫ヒストケミカル差異を調査していなかった.
研究 の 目的:
- インスリン腫細胞におけるグルコーストランスポーター (1-3),グルコキナーゼ,およびグルカゴン様ペプチド-1受容体発現における免疫ヒスト化学的差異を調査する.
- これらの発現レベルと臨床的低血糖現象型 (断食対食後の) を相関させる.
主な方法:
- 切断された6つの臓サンプルから採取したインスリン腫細胞の免疫ヒストキミカル分析.
- グルコーストランスポーター1-3,グルコキナーゼ,およびグルカゴン型ペプチド-1受容体発現の評価.
- 臨床的低血糖プロファイル (断食および食後の) との相関.
主要な成果:
- 断食後の低血糖症を患った1人の患者は,空腹と断食後の低血糖症の両方を患った5人の患者と比較して,グルコーストランスポーター2,グルコキナーゼ,GLP-1受容体のより高い発現を示した.
- グルコーストランスポーター1および3の発現は,すべての患者で最小か全くなかった.
- グルコースキナーゼとGLP-1受容体の発現の低下は,頻繁に断食中の低血糖症を患っている患者で観察されました.
結論:
- インスリン腫細胞におけるグルコーストランスポーター2の増加とグルコキナーゼおよびGLP-1受容体発現の低下は,特定の低血糖プロファイルと関連している可能性があります.
- これらの発見は,インスリン腫の異なる臨床的症状の基礎にある分子メカニズムについての洞察を提供します.
キーワード:
GCKCK GCK GCK GCK GCK GCK GCK GCK GCK GCK GCK GCKGLP-1RRについてGLUT2 GLUT2 GLUT2 GLUT2 GLUT2 GLUT2 GLUT2 GLUT2 GLUT2インスリノーマ (insulinoma) とはさらに関連する動画
関連する概念動画
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.6K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.6K
Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Hypoglycemia and Glucagon
1.0K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.0K
Oral Hypoglycemic Agents: Glinides
700
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
700
Insulin Secretory Vesicles
7.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
7.0K
Diabetes Mellitus: Overview and Type I Subtype
5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K


